PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.
about
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures.Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signaturesFrequent transmission of the Mycobacterium tuberculosis Beijing lineage and positive selection for the EsxW Beijing variant in Vietnam
P2860
PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
PEGylation does not significan ...... r subcutaneous administration.
@en
type
label
PEGylation does not significan ...... r subcutaneous administration.
@en
prefLabel
PEGylation does not significan ...... r subcutaneous administration.
@en
P2093
P50
P356
P1476
PEGylation does not significan ...... er subcutaneous administration
@en
P2093
John M Haynes
Linda J Chan
Victoria M McLeod
P304
P356
10.1021/MP5006189
P407
P577
2015-02-18T00:00:00Z